Piperacillin-tazobactam treatment for severe intra-abdominal infections.
In this limited series of 23 patients suffering from severe or life-threatening intra-abdominal infection, piperacillin + tazobactam, together with adequate surgical drainage and resections, cured 78% of our patients and eradicated almost all the pathogens. Side effects included essentially eosinophilia and elevation of transaminases but was never severe. Piperacillin + tazobactam seem thus to be an acceptable treatment, associated with correct surgical drainage. This regimen has to be compared in appropriate trial versus gold standard therapy, such as imipenem, a beta-lactam with aminoglucoside and imidazole or clindamycin or with broad spectrum beta-lactam and other inhibitors or beta-lactamases, but our rate of cure is impressive in such a population.
Legrand
J C
JC
Department of Internal Medicine, Hôpital Civil de Charleroi, Belgium.
Bastin
F
F
Belva
P
P
Chastel
C
C
Renaux
J
J
Van Eukem
P
P
D000005:Abdomen / Q000601:surgery; D000328:Adult; D000368:Aged; D004322:Drainage; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D004802:Eosinophilia / Q000139:chemically induced; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000601:surgery; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D010397:Penicillanic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D010878:Piperacillin / Q000008:administration & dosage* / Q000009:adverse effects; D000078142:Tazobactam; D065093:beta-Lactamase Inhibitors
D065093:beta-Lactamase Inhibitors; D010397:Penicillanic Acid; D000078142:Tazobactam; D010878:Piperacillin